Cardiotoxicity and Cardioprotection in Childhood Cancer
Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, Franco VI, Miller TL. Cardiotoxicity and Cardioprotection in Childhood Cancer. Acta Haematologica 2014, 132: 391-399. PMID: 25228565, DOI: 10.1159/000360238.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnthracyclinesAntineoplastic AgentsCardiotonic AgentsEvidence-Based PracticeGamma RaysHeart DiseasesHumansNeoplasmsRisk FactorsConceptsAnthracycline cumulative doseAdverse late effectsSignificant cardiovascular diseaseUse of dexrazoxaneLong-term cardioprotectionAnthracycline chemotherapyCardiovascular damageCardioprotective strategiesOncological efficacyCardiac damageBlack raceCumulative doseFemale sexRisk factorsChildhood cancerCardiotoxic effectsCardiovascular diseaseLate effectsHigh riskHigh doseGenetic predispositionCardiotoxicityYounger ageTrisomy 21Nutritional supplementsAnthracycline-related cardiotoxicity in childhood cancer survivors
Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW, Miller TL. Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion In Cardiology 2014, 29: 103-112. PMID: 24284979, DOI: 10.1097/hco.0000000000000034.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnthracycline-related cardiotoxicityCardiovascular complicationsAnthracycline treatmentRisk factorsCardioprotective agentGrowth hormone replacement therapyPrevention of cardiotoxicityHormone replacement therapySerious cardiovascular complicationsChildhood cancer survivorsLong-term outcomesUse of biomarkersDosage of anthracyclinesCardiac transplantationCardiac dysfunctionCancer survivorsCardiac injuryClinical manifestationsReplacement therapyEarly recognitionChildhood cancerCardiotoxic effectsΒ-blockersEnzyme inhibitorsCardiotoxicity